Evidence map›Paper›PMID 32340935›Full record

ArticleIEEE transactions on bio-medical engineering2021

Deep Convolutional Neural Networks and Transfer Learning for Measuring Cognitive Impairment Using Eye-Tracking in a Distributed Tablet-Based Environment.

Rafi U Haque, Alvince L Pongos, Cecelia M Manzanares, James J Lah, Allan I Levey, Gari D Clifford

Open access · greenAbstract read
In one paragraph

Article in IEEE transactions on bio-medical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rafi U Haque
Alvince L Pongos
Cecelia M Manzanares
James J Lah
Allan I Levey
Gari D Clifford
Emory and Henry College · USGeorgia Institute of Technology · US

Funding

The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's DiseaseR01AG070937 · NIA · EMORY UNIVERSITY · PI LAH, JAMES J · 2021 to 2025
$35.2M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Jonathan David Glass · 2020 to 2026
$29.0M
The Emory Alzheimer's Disease CenterP50AG025688 · NIA · EMORY UNIVERSITY · PI WINGO, THOMAS SPURGEON · 2005 to 2019
$25.7M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
NIA NIH HHS P30 AG066511NIA NIH HHS P50 AG025688NIA NIH HHS R01 AG070937NIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

objectiveAlzheimer's disease (AD) is a neurodegenerative disorder that initially presents with memory loss in the presence of underlying neurofibrillary tangle and amyloid plaque pathology. Mild cognitive impairment is the initial symptomatic stage, which is an early window for detecting cognitive impairment prior to progressive decline and dementia. We recently developed the Visuospatial Memory Eye-Tracking Test (VisMET), a passive task capable of classifying cognitive impairment in AD in under five minutes. Here we describe the development of a mobile version of VisMET to enable efficient and widespread administration of the task.

methodsWe delivered VisMET on iPad devices and used a transfer learning approach to train a deep neural network to track eye gaze. Eye movements were used to extract memory features to assess cognitive status in a population of 250 individuals.

resultsMild to severe cognitive impairment was identifiable with a test accuracy of 70%. By enforcing a minimal eye tracking calibration error of 2 cm, we achieved an accuracy of 76% which is equivalent to the accuracy obtained using commercial hardware for eye-tracking.

conclusionThis work demonstrates a mobile version of VisMET capable of estimating the presence of cognitive impairment. SIGNIFICANCE: Given the ubiquity of tablet devices, our approach has the potential to scale globally.

Indexed as

Alzheimer DiseaseCognitive DysfunctionEye-Tracking TechnologyHumansMachine LearningNeural Networks, Computer

Identifiers

PMID32340935
PMCPMC9216227
OpenAlexW3020531458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.